How Much Does Retatrutide Cost in Tennessee in 2026?

What Tennessee Residents Pay for Retatrutide at Retail Pharmacies

The cash-pay price for brand-name retatrutide at Tennessee retail pharmacies ranges from approximately $1,000 to $1,100 per month for maintenance doses, consistent with Eli Lilly's national list price. This figure applies to patients purchasing the drug without any insurance benefit or discount program.

Tennessee has roughly 40 counties classified as medically underserved by HRSA, and pharmacy pricing can shift based on local competition. A patient filling retatrutide at a chain pharmacy in Nashville or Memphis may see slightly lower cash prices than someone at a single-location pharmacy in rural East Tennessee, though the difference rarely exceeds $50 per month. GoodRx-style discount aggregators have begun listing retatrutide coupons that bring cash-pay costs to the $900 to $1,000 range at select Tennessee locations.

The state's adult obesity prevalence sits at 38.9%, ranking Tennessee among the top ten states by that measure according to CDC Behavioral Risk Factor Surveillance System data [1]. That rate translates to roughly 2.1 million adults who could meet prescribing criteria. Demand at this scale means Tennessee pharmacies stock retatrutide more reliably than pharmacies in lower-prevalence states, and supply disruptions have been less frequent here than the shortages that affected semaglutide in 2023 and 2024 [2].

For context, the phase 2 trial of retatrutide (N=338) published by Jastreboff and colleagues in the New England Journal of Medicine showed that the highest dose (12 mg weekly) produced 24.2% mean body-weight reduction at 48 weeks versus 2.1% for placebo [3]. That degree of efficacy has driven strong patient demand across the state, and it partially explains why Eli Lilly set pricing in line with tirzepatide (Zepbound) rather than discounting below it.

How Tennessee Insurance Plans Handle Retatrutide Coverage

Most large commercial insurers operating in Tennessee, including BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, and Aetna, have added retatrutide to their formularies with prior authorization requirements. Coverage typically requires documented BMI ≥30 kg/m² (or ≥27 with at least one weight-related comorbidity), a failed trial of lifestyle modification lasting 6 months or more, and prescriber attestation that the patient is enrolled in a behavioral counseling program.

Copays after prior authorization approval vary widely. Preferred-tier placement on a commercial plan may yield copays of $50 to $150 per month. Non-preferred placement pushes that to $200 to $550. Some self-insured employer plans in Tennessee exclude anti-obesity medications entirely, which means even prior authorization cannot reveal coverage.

The Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity states: "Third-generation incretin-based therapies, including triple agonists, should be considered as first- or second-line pharmacotherapy for patients with BMI ≥30 kg/m² given their superior efficacy profile" [4]. Tennessee prescribers increasingly reference this guideline when submitting prior authorization appeals, and approval rates have improved as a result.

Patients denied coverage on first attempt should request the specific denial reason in writing, then file a formal appeal citing the Endocrine Society guideline language and the patient's documented comorbidities. In Tennessee, external review through the Department of Commerce and Insurance is available if internal appeals fail. That external review process takes 30 to 45 days on average.

TennCare and Retatrutide: What Medicaid Covers

TennCare, Tennessee's Medicaid program, does not cover retatrutide for chronic weight management as of May 2026. Coverage is limited to type 2 diabetes indications only, and even that pathway requires prior authorization demonstrating inadequate glycemic control on metformin plus one additional oral agent.

This gap affects a large population. Roughly 1.7 million Tennesseans are enrolled in TennCare, and obesity prevalence among Medicaid beneficiaries nationally exceeds 40% according to CDC estimates [1]. The American Association of Clinical Endocrinology (AACE) has called for broader Medicaid coverage of GLP-1 receptor agonists for obesity, noting in their 2023 consensus statement: "Restricting access to evidence-based obesity pharmacotherapy in Medicaid populations perpetuates health disparities and increases long-term costs from obesity-related complications" [5].

Tennessee legislators introduced SB-1247 in the 2026 session, which would mandate TennCare coverage of FDA-approved anti-obesity medications for beneficiaries with BMI ≥35. The bill remains in committee. Even if passed, implementation would likely take 12 to 18 months for formulary updates, prior authorization criteria development, and managed care organization contract amendments.

For TennCare enrollees who need retatrutide now, two options exist: the Eli Lilly Patient Assistance Program (income-based, covering patients at or below 400% of the federal poverty level) and compounded retatrutide through a licensed 503A pharmacy, paid out of pocket.

Compounded Retatrutide in Tennessee: Legal Status and Pricing

Compounded retatrutide is legal in Tennessee through state-licensed 503A compounding pharmacies operating under a valid patient-specific prescription. Tennessee's Board of Pharmacy permits 503A compounding as long as the pharmacy holds a current Tennessee compounding license and the prescriber provides an individualized prescription for a named patient [6].

Prices from Tennessee 503A compounders range from $250 to $500 per month depending on dose, concentration, and whether the pharmacy sources domestically manufactured retatrutide API or imports it. Pharmacies in Nashville, Knoxville, and Chattanooga have emerged as the primary compounding hubs for peptide-based weight-management drugs.

A few important caveats apply. Compounded retatrutide is not FDA-approved, does not carry the same potency and sterility guarantees as brand-name product, and is not covered by any insurance plan. The FDA has taken enforcement action against 503B outsourcing facilities that distributed compounded GLP-1 receptor agonists without proper registration, but individual 503A pharmacies filling patient-specific prescriptions have generally not been targeted [6].

Patients considering compounded retatrutide should verify three things: the pharmacy's active Tennessee Board of Pharmacy license, third-party potency and sterility testing documentation (USP 797 and 800 compliance), and whether the prescribing clinician has reviewed the compounding pharmacy's certificate of analysis. Skipping this verification step exposes patients to under-dosed or contaminated product, a risk that has materialized with compounded semaglutide in other states.

Telehealth Prescribing of Retatrutide in Tennessee

Tennessee permits telehealth prescribing of retatrutide under the state's Telehealth Parity Act (Tenn. Code Ann. § 63-1-155), which requires only that the prescriber establish a valid provider-patient relationship through a synchronous audio-video visit. No in-person visit is required before the initial prescription.

This makes retatrutide accessible to patients in Tennessee's 58 rural counties where endocrinology and obesity-medicine specialists are scarce. The Tennessee Medical Association reported in 2025 that only 14 board-certified obesity medicine physicians practice outside the Nashville, Memphis, Knoxville, and Chattanooga metro areas. Telehealth closes that gap efficiently.

Several national telehealth platforms now prescribe retatrutide to Tennessee residents, with monthly program fees ranging from $99 to $199 on top of medication costs. HealthRX offers telehealth-based retatrutide prescribing in Tennessee with physician oversight, lab monitoring protocols, and dose-titration guidance included in the visit fee.

Patients using telehealth for retatrutide should confirm that their prescriber holds an active Tennessee medical license (verifiable through the Tennessee Board of Medical Examiners) and that the platform's pharmacy partner ships to their Tennessee address. Controlled-substance restrictions do not apply to retatrutide since it is not a DEA-scheduled medication.

Eli Lilly Savings Programs and Tennessee Discount Options

Eli Lilly operates two primary savings mechanisms for retatrutide: the manufacturer savings card and the Lilly Patient Assistance Program. Both are available to Tennessee residents.

The savings card reduces out-of-pocket costs for commercially insured patients to as low as $25 per month for up to 24 months. Patients must carry commercial insurance that covers retatrutide (even at a high copay tier) to qualify. The card cannot be combined with Medicare, Medicaid, TRICARE, or other government-funded insurance. In practice, a Tennessee patient with a $400 monthly copay after insurance would pay $25, with Lilly covering the $375 difference up to an annual cap.

The Patient Assistance Program provides brand-name retatrutide at no cost to uninsured patients with household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026). Applications require income documentation and prescriber signature. Approval takes 2 to 4 weeks, and medication ships directly to the patient's Tennessee address or to the prescriber's office.

Tennessee-specific options beyond Lilly's programs include: prescription assistance through the Tennessee Drug Card (a state-supported discount card accepted at most chain pharmacies), NeedyMeds database listings for retatrutide-specific assistance funds, and sliding-scale pricing at federally qualified health centers (FQHCs) that have added obesity pharmacotherapy to their formularies. Tennessee has 29 FQHCs with 217 service delivery sites, and a growing number stock or can order retatrutide for their patient panels.

How Retatrutide Pricing Compares to Other Anti-Obesity Medications in Tennessee

Retatrutide's list price sits in the same band as tirzepatide (Zepbound, ~$1,060/month) and slightly above semaglutide 2.4 mg (Wegovy, ~$1,350/month) after Novo Nordisk's 2025 list-price adjustment [7]. The relevant comparison, though, is cost per percentage point of weight loss, where retatrutide's clinical data suggests a potential advantage.

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks [8]. Semaglutide 2.4 mg in the STEP-1 trial (N=1,961) produced 14.9% at 68 weeks [9]. Retatrutide's phase 2 data showed 24.2% at 48 weeks at the 12 mg dose, with weight-loss curves that had not yet plateaued [3]. If phase 3 results confirm these numbers, retatrutide may deliver more weight loss per dollar spent than either competitor.

The triple-agonist mechanism (GIP, GLP-1, and glucagon receptors simultaneously) distinguishes retatrutide from dual agonists like tirzepatide. Dr. Ania Jastreboff of Yale, the lead investigator on the phase 2 trial, noted: "The addition of glucagon receptor agonism appears to contribute to greater energy expenditure and hepatic fat reduction beyond what GLP-1 and GIP agonism achieve alone" [3]. That hepatic fat effect is particularly relevant in Tennessee, where nonalcoholic fatty liver disease prevalence tracks closely with the state's high obesity rates.

Clinical Evidence Supporting Retatrutide

The foundational efficacy data for retatrutide comes from the phase 2, dose-ranging, randomized controlled trial published in the New England Journal of Medicine in June 2023 [3]. This 48-week study randomized 338 adults with obesity (BMI ≥30, or ≥27 with comorbidity) to one of several retatrutide doses or placebo.

Key findings at the 12 mg dose level: mean weight loss of 24.2% from baseline, with 26% of participants losing more than 30% of body weight. Waist circumference decreased by a mean of 18.4 cm. HbA1c in the subset with prediabetes dropped by 0.4 percentage points, suggesting metabolic benefit even in patients without overt diabetes [3].

Adverse events followed the expected GI pattern seen with other incretin-based therapies. Nausea occurred in 45% of participants at the 12 mg dose (versus 12% with placebo), vomiting in 17%, and diarrhea in 20%. Most GI events were mild to moderate, peaked during dose escalation, and resolved without treatment discontinuation [3]. The dropout rate due to adverse events was 6% across all retatrutide arms.

The TRIUMPH phase 3 program includes four trials evaluating retatrutide in chronic weight management, type 2 diabetes, obstructive sleep apnea, and cardiovascular outcomes [10]. Completion of the weight-management trial (TRIUMPH-1) provided the registration data for FDA review. The cardiovascular outcomes trial remains ongoing, with primary completion expected in 2028.

For Tennessee clinicians deciding between retatrutide and other options, the 2023 AACE Obesity Algorithm recommends selecting pharmacotherapy based on the degree of weight loss needed, comorbidity profile, and cost-access considerations [5]. A patient needing more than 20% weight loss to reach a clinically meaningful threshold may be better served by retatrutide than by semaglutide, provided cost and access barriers can be managed.

Liver fat reduction data from the phase 2 trial showed a 42.9% relative reduction in hepatic fat fraction at the 12 mg dose measured by MRI-PDFF, a finding that has generated interest from hepatologists managing metabolic dysfunction-associated steatotic liver disease (MASLD) [3]. Tennessee's MASLD burden, estimated at 30 to 35% of the adult population based on national NHANES projections [11], makes this dual benefit especially relevant for prescribers in the state.